GB0501540D0 - Controlled production and delivery of biologically active agents by gut bacteria - Google Patents

Controlled production and delivery of biologically active agents by gut bacteria

Info

Publication number
GB0501540D0
GB0501540D0 GBGB0501540.9A GB0501540A GB0501540D0 GB 0501540 D0 GB0501540 D0 GB 0501540D0 GB 0501540 A GB0501540 A GB 0501540A GB 0501540 D0 GB0501540 D0 GB 0501540D0
Authority
GB
United Kingdom
Prior art keywords
biologically active
delivery
active agents
controlled production
gut bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0501540.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Priority to GBGB0501540.9A priority Critical patent/GB0501540D0/en
Publication of GB0501540D0 publication Critical patent/GB0501540D0/en
Priority to KR1020077019503A priority patent/KR101291960B1/ko
Priority to JP2007551749A priority patent/JP4989490B2/ja
Priority to ES06701043T priority patent/ES2353721T3/es
Priority to DE602006017331T priority patent/DE602006017331D1/de
Priority to CA2640343A priority patent/CA2640343C/en
Priority to PCT/GB2006/000222 priority patent/WO2006079790A2/en
Priority to EP06701043A priority patent/EP1841875B1/en
Priority to US11/814,739 priority patent/US7988961B2/en
Priority to AT06701043T priority patent/ATE483811T1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0501540.9A 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria Ceased GB0501540D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
AT06701043T ATE483811T1 (de) 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien
DE602006017331T DE602006017331D1 (de) 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien
JP2007551749A JP4989490B2 (ja) 2005-01-25 2006-01-24 腸内細菌による生物活性物質の制御された産生および送達
ES06701043T ES2353721T3 (es) 2005-01-25 2006-01-24 Administración y producción controladas de agentes biológicamente activos mediante bacterias intestinales.
KR1020077019503A KR101291960B1 (ko) 2005-01-25 2006-01-24 장내세균에 의한 생물학적 활성제의 제어된 생산 및 전달
CA2640343A CA2640343C (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria
EP06701043A EP1841875B1 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria
US11/814,739 US7988961B2 (en) 2005-01-25 2006-01-24 Gut commensal bacterium and methods of using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria

Publications (1)

Publication Number Publication Date
GB0501540D0 true GB0501540D0 (en) 2005-03-02

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0501540.9A Ceased GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria

Country Status (10)

Country Link
US (1) US7988961B2 (https=)
EP (1) EP1841875B1 (https=)
JP (1) JP4989490B2 (https=)
KR (1) KR101291960B1 (https=)
AT (1) ATE483811T1 (https=)
CA (1) CA2640343C (https=)
DE (1) DE602006017331D1 (https=)
ES (1) ES2353721T3 (https=)
GB (1) GB0501540D0 (https=)
WO (1) WO2006079790A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317000B2 (en) * 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (en) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumour-specific bacterial promoter elements
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
WO2015095796A1 (en) 2013-12-20 2015-06-25 President And Fellows Of Harvard College An engineered genetic enteric sensor bacteria and uses thereof
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
AU2015369627A1 (en) * 2014-12-22 2017-07-06 Massachusetts Institute Of Technology Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
BR112017018656B1 (pt) * 2015-03-02 2021-11-30 Synlogic, Inc Bactéria geneticamente modificada, composição farmaceuticamente aceitável compreendendo a dita bactéria e uso da dita composição para tratar ou prevenir uma doença ou condição associada à inflamação intestinal e/ou função da barreira intestinal comprometida
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017087580A1 (en) 2015-11-16 2017-05-26 Synlogic, Inc. Bacteria engineered to reduce hyperphenylalaninemia
AU2017252409B2 (en) 2016-04-20 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
US20200268813A1 (en) * 2017-02-15 2020-08-27 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
JP2020516318A (ja) * 2017-04-17 2020-06-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 操作された共生細菌及び使用方法
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
JP2022512380A (ja) 2018-12-10 2022-02-03 ノヴォム バイオテクノロジーズ，インコーポレイテッド 高シュウ酸尿症を治療するための方法及び組成物
CN115298308A (zh) 2020-03-20 2022-11-04 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
JP2003509046A (ja) * 1999-09-10 2003-03-11 イギリス国 組換え微生物
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−１，３−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−１，３−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Also Published As

Publication number Publication date
KR101291960B1 (ko) 2013-08-09
EP1841875B1 (en) 2010-10-06
EP1841875A2 (en) 2007-10-10
WO2006079790A2 (en) 2006-08-03
JP4989490B2 (ja) 2012-08-01
KR20070108882A (ko) 2007-11-13
CA2640343C (en) 2014-01-14
CA2640343A1 (en) 2006-08-03
DE602006017331D1 (de) 2010-11-18
WO2006079790A3 (en) 2006-12-21
ES2353721T3 (es) 2011-03-04
US7988961B2 (en) 2011-08-02
ATE483811T1 (de) 2010-10-15
JP2008527988A (ja) 2008-07-31
US20080131402A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
GB0501540D0 (en) Controlled production and delivery of biologically active agents by gut bacteria
NZ596658A (en) Dig-10 insecticidal cry toxins
UA103215C2 (uk) Поліпептид з ксиланазною активністю
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
ES2534744T3 (es) Plasmina modificada de forma recombinante
PE20120206A1 (es) Variantes de polipeptidos receptores de activina iib
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
PE20130593A1 (es) DOMINIOS DE FIBRONECTINA TIPO III A LA DECIMA (10Fn3) MODIFICADOS DE UNION A SEROALBUMINA
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
MX2018005387A (es) Variantes de fgf21.
UA106869C2 (uk) Поліпептид ace2
NO20076043L (no) Glucagon-lignende peptid-2 (GLP-2) analoger
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
NZ602702A (en) Modified fgf-21 polypeptides and their uses
WO2020044296A3 (en) Recombinant lectin variants
PE20121722A1 (es) Polipeptido de fusion contra tumor inducido por virus eb y mutante de colicina ia
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
MX2020005670A (es) Variantes de expresión de cdkl5 y proteínas de fusión de cdkl5.
PH12020500338A1 (en) Acylated oxyntomodulin peptide analog
NZ596501A (en) Casb7439 constructs
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
ES2585185T3 (es) Polipéptidos quiméricos y sus aplicaciones terapéuticas contra una infección por Flaviviridae

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)